Is There an Increased Risk of Hepatotoxicity with Metamizole? A Comparative Cohort Study in Incident Users.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
accepted:
26
05
2021
pubmed:
18
7
2021
medline:
21
4
2022
entrez:
17
7
2021
Statut:
ppublish
Résumé
The analgesic metamizole, which has been withdrawn from the market in several countries due to the risk of agranulocytosis but is still available on the market in Germany and some other countries, has been associated with liver injury in published case reports; however, epidemiological studies on the risk of liver injury are limited. The aim of this study was to compare the risk of liver injury up to 270 days after the first start of treatment with metamizole with the corresponding risk in patients starting treatment with paracetamol, using a retrospective cohort incident user design. The first prescription for either metamizole or paracetamol in the Intercontinental Medical Statistics (IMS) Metamizole was associated with a higher risk of liver injury compared with paracetamol (adjusted hazard ratio 1.69, 95% confidence interval 1.46-1.97). Sensitivity analyses were performed to evaluate the robustness of these findings. In all the sensitivity analyses, metamizole was still associated with a higher risk of liver injury, including an analysis where naproxen was used as a comparator instead of paracetamol. Results from this study support previous studies suggesting that metamizole is associated with a significant risk of liver injury. Nevertheless, a possible impact of residual confounding cannot be excluded.
Identifiants
pubmed: 34273099
doi: 10.1007/s40264-021-01087-7
pii: 10.1007/s40264-021-01087-7
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Acetaminophen
362O9ITL9D
Dipyrone
6429L0L52Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
973-985Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
European Medicines Agency. CHMP. Assessment report, Referral under Article 31 of Directive 2001/83/EC, metamizole-containing medicinal products. London: European Medicines Agency. 2021.
Volz M, Kellner HM. Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol. 1980;10(Suppl 2):299–308.
Levy M, Zylber-Katz E, Rosenkranz B. Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet. 1995;28(3):216–34.
pubmed: 7758252
Lutz M. Metamizole (dipyrone) and the liver: a review of the literature. J Clin Pharmacol. 2019;59(11):1433–42.
pubmed: 31433499
Okonek S. Intoxication with pyrazolones. Br J Clin Pharmacol. 1980;10(Suppl 2):385s-s390.
pubmed: 6969085
pmcid: 1430168
Monov A, Chernev K, Penkova S, Boshnakova T. Acute kidney failure and acute toxic cholestatic hepatitis caused by a large amount of analgin [in Bulgarian]. Vutr Boles. 1985;24(1):133–6.
pubmed: 4024603
Gao Y, Yu K-J, Wang H-L, Liu H-T. Liver injury and acute renal failure following combined use of paracetamol and metamizole sodium. Adverse Drug React J. 2012;14(6):387–93.
Björnsson ES. Liver injury associated with the analgetic drug metamizole. Br J Clin Pharmacol. 2020;86(7):1248–50.
pubmed: 32400058
pmcid: 7319005
Weber S, Benesic A, Gerbes AL. Further evidence for the hepatotoxic potential of metamizole. Br J Clin Pharmacol. 2021;87(3):1587–8.
pubmed: 32696537
Federmann G, Becker EW, Tautorat H, Penschuck C, Berg PA. Demonstration by lymphocyte transformation test of the allergic genesis in a case of acute hepatitis [in German]. Deutsche medizinische Wochenschrift (1946). 1988;113(43):1676–9.
Herdeg C, Hilt F, Buchtemann A, Bianchi L, Klein R. Allergic cholestatic hepatitis and exanthema induced by metamizole: verification by lymphocyte transformation test. Liver. 2002;22(6):507–13.
pubmed: 12445177
Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. Br J Clin Pharmacol. 2015;79(6):988–99.
pubmed: 25444550
pmcid: 4456131
Benesic A, Rotter I, Dragoi D, Weber S, Buchholtz M-L, Gerbes AL. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2018;16(9):1488-94.e5.
pubmed: 29723689
Krisai P, Rudin D, Grünig D, Scherer K, Pichler W, Terracciano L, et al. Acute liver failure in a patient treated with metamizole. Front Pharmacol. 2019;10:996.
pubmed: 31572180
pmcid: 6749849
Sebode M, Reike-Kunze M, Weidemann S, Zenouzi R, Hartl J, Peiseler M, et al. Metamizole: an underrated agent causing severe idiosyncratic drug-induced liver injury. Br J Clin Pharmacol. 2020;86(7):1406–15.
pubmed: 32080881
pmcid: 7319009
Teschke R, Eickhoff A, Brown AC, Neuman MG, Schulze J. Diagnostic biomarkers in liver injury by drugs, herbs, and alcohol: tricky dilemma after EMA correctly and officially retracted letter of support. Int J Mol Sci. 2019;21(1):212.
pmcid: 6981464
Teschke R, Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-Mid 2020: a comprehensive analysis. Med (Basel). 2020;7(10):62.
Sabate M, Ibanez L, Perez E, Vidal X, Buti M, Xiol X, et al. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther. 2007;25(12):1401–9.
pubmed: 17539979
Rotundo L, Pyrsopoulos N. Liver injury induced by paracetamol and challenges associated with intentional and unintentional use. World J Hepatol. 2020;12(4):125–36.
pubmed: 32685105
pmcid: 7336293
Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87–93.
pubmed: 16820551
Mazaleuskaya LL, Sangkuhl K, Thorn CF, FitzGerald GA, Altman RB, Klein TE. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015;25(8):416–26.
pubmed: 26049587
pmcid: 4498995
Kurtovic J, Riordan SM. Paracetamol-induced hepatotoxicity at recommended dosage. J Intern Med. 2003;253(2):240–3.
pubmed: 12542566
Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, et al. Causality of drugs involved in acute liver failure leading to transplantation: results from the study of acute liver transplant (SALT). Drug Saf. 2013;36(9):757–64.
pubmed: 23743692
Gulmez SE, Larrey D, Pageaux G-P, Lignot S, Lassalle R, Jové J, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135–44.
pubmed: 23325533
pmcid: 3568201
Gulmez SE, Larrey D, Pageaux GP, Bernuau J, Bissoli F, Horsmans Y, et al. Liver transplant associated with paracetamol overdose: results from the seven-country SALT study. Br J Clin Pharmacol. 2015;80(3):599–606.
pubmed: 26017643
pmcid: 4574844
Moore N, Duret S, Grolleau A, Lassalle R, Barbet V, Duong M, et al. Previous drug exposure in patients hospitalised for acute liver injury: a case-population study in the french national healthcare data system. Drug Saf. 2011;42(4):559–72.
Raza A, Chan V, Atiq MU. Idiosyncratic drug reaction: a rare mechanism of acute tylenol toxicity. Cureus. 2019;11(11):6099.
Guengerich FP. A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicol Res. 2020;37(1):1–23.
pmcid: 7431904
Kalsi SS, Dargan PI, Waring WS, Wood DM. A review of the evidence concerning hepatic glutathione depletion and susceptibility to hepatotoxicity after paracetamol overdose. Open Access Emerg Med. 2011;3:87–96.
pubmed: 27147856
pmcid: 4753970
Roth RA, Ganey PE. Intrinsic versus idiosyncratic drug-induced hepatotoxicity—two villains or one? J Pharmacol Exp Ther. 2010;332(3):692–7.
pubmed: 20019161
pmcid: 2835443
Donato M, Tolosa L. High-content screening for the detection of drug-induced oxidative stress in liver cells. Antioxidants (Basel). 2021;10(1):106.
pubmed: 33451093
pmcid: 7828515
Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66(6):1154.
pubmed: 28341748
Ye H, Nelson LJ, Gómez Del Moral M, Martínez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. World J Gastroenterol. 2018;24(13):1373–85.
pubmed: 29632419
pmcid: 5889818
Uetrecht J. Mechanistic studies of idiosyncratic DILI: clinical implications. Front Pharmacol. 2019;10:837.
pubmed: 31402866
pmcid: 6676790
Eakins R, Walsh J, Randle L, Jenkins RE, Schuppe-Koistinen I, Rowe C, et al. Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome. Sci Rep. 2015;5:16423.
pubmed: 26607827
pmcid: 4660393
Kane AE, Huizer-Pajkos A, Mach J, McKenzie C, Mitchell SJ, de Cabo R, et al. N-Acetyl cysteine does not prevent liver toxicity from chronic low-dose plus subacute high-dose paracetamol exposure in young or old mice. Fundam Clin Pharmacol. 2016;30(3):263–75.
pubmed: 26821200
pmcid: 4864111
Mishima-Iwai M, Takahashi K, Yokode M, Kimura Y, Sawai Y, Ueda Y, et al. Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity. Hepatol Res. 2015;45(7):814–7.
pubmed: 25088083
Shinzawa H, Togashi H, Sugahara K, Ishibashi M, Terui Y, Aoki M, et al. Acute cholestatic hepatitis caused by a probable allergic reaction to paracetamol in an adolescent. Tohoku J Exp Med. 2001;193(3):255–8.
pubmed: 11315774
Hoffmann F, Bantel C, von Rosen FT, Jobski K. Regional differences in prescribing patterns of metamizole in germany based on data from 70 million persons. Int J Environ Res Public Health. 2020;17(11):3892.
pmcid: 7312502
Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol. 1994;47(7):731–7.
pubmed: 7722586
Becher H, Kostev K, Schroder-Bernhardi D. Validity and representativeness of the “Disease Analyzer” patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther. 2009;47(10):617–26.
pubmed: 19825325
Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56(10):459–66.
pubmed: 30168417
Hayashi PH. Overview of causality assessment in drug-induced liver injury. Clin Liver Dis. 2017;9(2):29–33.
Roussel Uclaf Causality Assessment Method (RUCAM) in drug induced liver injury. LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2019.
Brockow K, Przybilla B, Aberer W, Bircher AJ, Brehler R, Dickel H, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). Allergo J Int. 2015;24(3):94–105.
pubmed: 26120552
pmcid: 4479479
Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96-108.e4.
pubmed: 24681128
Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1–6.
pubmed: 23023988
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
pubmed: 26517184
Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17(2):224.
pubmed: 26861310
pmcid: 4783956
Heinze G, Dunkler D. Five myths about variable selection. Transpl Int. 2017;30(1):6–10.
pubmed: 27896874
Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018:5253623.
pubmed: 29568654
pmcid: 5820561
Schmeltzer PA, Kosinski AS, Kleiner DE, Hoofnagle JH, Stolz A, Fontana RJ, et al. Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int. 2016;36(4):603–9.
pubmed: 26601797
Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol. 2010;16(45):5651–61.
pubmed: 2997980
pmcid: 2997980
Renoux C, Dell’Aniello S, Brenner B, Suissa S. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiol Drug Saf. 2017;26(5):554–60.
pubmed: 28326633
Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221–8.
pubmed: 26954351
pmcid: 4778958
Coleman CI, Antz M, Ehlken B, Evers T. REal-LIfe Evidence of stroke prevention in patients with atrial fibrillation—the RELIEF study. Int J Cardiol. 2016;203:882–4.
pubmed: 26605688
Coleman CI, Antz M. Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). Intern Emerg Med. 2017;12(3):419–22.
pubmed: 28194695
Forns J, Cainzos-Achirica M, Hellfritzsch M, Morros R, Poblador-Plou B, Hallas J, et al. Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: a study in three European data sources. Pharmacoepidemiol Drug Saf. 2019;28(7):965–75.
pubmed: 31172633
pmcid: 6618105
Yoon E, Babar A, Choudhary M, Kutner M, Pyrsopoulos N. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;4(2):131–42.
pubmed: 27350943
pmcid: 4913076
Amacher DE. Female gender as a susceptibility factor for drug-induced liver injury. Hum Exp Toxicol. 2014;33(9):928–39.
pubmed: 24299907
Buzzetti E, Parikh PM, Gerussi A, Tsochatzis E. Gender differences in liver disease and the drug-dose gender gap. Pharmacol Res. 2017;120:97–108.
pubmed: 28336373